Alphabet's GV and Verily are getting behind an ambitious biotech venture that aims to develop a new treatment for cardiovascular disease.
Alphabet's Verily and GV are getting behind an ambitious new venture called Verve Therapeutics.
For Alphabet, Verve represents a potential path to revenue in one of its most important early-stage science projects incubated in X , the research and development lab that was also home to Waymo's self-driving cars, Wing's delivery drones and the Chronicle cybersecurity project.raised $1 billion In its early days, Verily was known as Google Life Sciences. One of its projects was focused on nanoparticles, or tiny particles that can be used to help make drug treatments more targeted. Google had a group of engineers and scientists working on the technology for years.that it began the research to find new ways to treat disease, including with potentially new drugs.
In the U.S., more than 600,000 fatalities per year are attributed to heart disease despite the billions of dollars spent by pharmaceutical companies on potential treatments. Kathiresan said Verve's initial focus is a rare disease that's associated with extremely high cholesterol levels and impacts about 1 in a million people. From there, Verve hopes to provide new one-time injectable treatment to replace pills.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
US-China talks break up after US raises tariffsUS-China talks break up with no deal after Trump hikes tariffs on $200 billion in Chinese imports
Weiterlesen »
U.S. CEO group says rising U.S.-China tariffs could hurt economyBusiness Roundtable, a group of U.S. corporate chief executive officers, said on...
Weiterlesen »
U.S. Stocks Plummet As U.S.-China Trade Dispute EscalatesU.S. equities and commodities are taking a hit as trade war tensions between the U.S. and China continue to escalate by theothersarahh
Weiterlesen »
US-China trade talks break up after US raises tariffsTrade talks between the US and China end without a deal, but negotiators from both sides say they held 'constructive' talks that went 'fairly well' after the US raised tariffs on $200 billion in Chinese goods and Beijing promised to retaliate.
Weiterlesen »
U.S. border agents apprehended nearly 100,000 people at southern border in April: dataU.S. border officers apprehended nearly 99,000 people crossing the U.S. southern...
Weiterlesen »
Monthly border apprehensions reach highest level since 2007U.S. border officers apprehended nearly 99,000 people crossing the U.S. southern...
Weiterlesen »
How automation can prevent us from controlling the systems that keep us safeThe pursuit of efficiency might actually be making us less safe. Edward Tenner, author of the Efficiency Paradox, details how automation can result in the exclusion of individuals necessary to keeping us safe when automated systems fail.
Weiterlesen »
U.S. poised to double tariffs on $200 billion of Chinese imports, escalating U.S.-China trade warU.S. poised to more than double tariffs on $200 billion of Chinese imports, escalating trade war; talks expected to resume Friday
Weiterlesen »
Treasury yields move lower as increased tariffs on China kick inU.S. government debt prices were higher on Friday morning as U.S.-China trade tensions escalate further.
Weiterlesen »
U.S. officials: Iran official OK'd attacks on U.S. militaryThree U.S. officials say that intelligence revealed Iran told some proxies and surrogates they could go after American military targets in the region.
Weiterlesen »